STT LOSS NOTICE: Rosen Law Firm Reminds State Street

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
105
STT LOSS NOTICE: Rosen Law Firm Reminds State Street Corporation Investors of Important Deadline in First Filed Class Action - STT

NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of State Street Corporation securities (NYSE: STT ) from February 27, 2012 through January 18, 2017, both dates inclusive (the “Class Period”) of the important March 28, 2017 lead plaintiff deadline in the first class action filed by Rosen Law Firm. The lawsuit seeks to recover damages for State Street investors under the federal securities laws.

To join the State Street class action, go to http://www.rosenlegal.com/cases-1031.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) State Street engaged in a scheme to defraud a number of its clients by secretly applying commissions to billions of dollars of securities trades; (2) State Street’s billing practices relied on unsustainable methodologies; (3) over a 18-year period, approximately $240 million or more of expenses may have been incorrectly invoiced to State Street’s asset servicing clients; (4) from June 2010 until September 2011, State Street charged clients “substantial” mark-ups without their consent; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1031.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com .

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising.  Prior results do not guarantee a similar outcome.

Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY  10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 37

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Pinterest Faces Legal Probe: Investor Concerns Rise

Updated Category News Views 95

Legal Storms Gather on Pinterest's Horizon I remember a time when Pinterest was the darling of Wall Street, but here we are, staring at an investigation that's got more layers than an onion. On November 6, 2026, news broke that Kahn Swick & Foti, LLC (KSF) is sniffing around Pinterest's officers and directors. This is no small fry since KSF is steered by none other than...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 77

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
U Power's H1 2026: Inside the Financial Numbers

Updated Category News Views 137

Financial Struggles Amid Expansion Efforts Imagine a ship trying to lift anchor while taking on water. That's U Power Limited's latest financials for the first half of 2026 in a nutshell. We're seeing the company, listed under NASDAQ: UCAR, navigating through turbulent financial seas while executing ambitious expansion projects. Revenue Declines Spell Trouble Total net...

Continue Reading
McKinley Irvin Earns Top 2027 Rankings in Family Law

Updated Category News Views 158

A Legal Eagle Soars High in 2027 Oh, the legal world can be as cutthroat as the stock market some days, especially when you're gunning for those top-tier rankings. This year, McKinley Irvin has managed to ruffle a few feathers in the Pacific Northwest, claiming top honors in the 2027 Best Law Firms rankings. And let me tell you, this wasn’t just handed to them on a...

Continue Reading
Beverly Hills Body Academy: A New Era in Contouring

Updated Category News Views 93

Setting New Standards in Body Contouring It's no secret that Beverly Hills is all about luxury and cutting-edge trends. So, when the Beverly Hills Body Academy™ (BHBA) sets up shop in this glitzy locale, it's a pretty loud statement in the world of body contouring. This isn't just another vanity-driven operation; it's about pioneering advancements in the field of body...

Continue Reading
Datavault AI's Turbulent Boardroom Saga Escalates

Updated Category News Views 201

The Corporate Chess Game at Datavault AI If there's one thing Wall Street hates, it's uncertainty. And boy, does Datavault AI (NASDAQ: DVLT) deliver plenty of it right now. Founder Nathaniel Bradley has lobbed a lawsuit at the board, claiming that Chairman and CFO Brett Moyer orchestrated a coup to oust him without proper board procedures. Talk about drama fit for a soap...

Continue Reading
APP Group's New Conservation Efforts in Sumatra

Updated Category News Views 215

Taking a Bold Step Towards Conservation APP Group, in collaboration with Proforest, WWF-Indonesia, and KKI WARSI, is setting its sights on a more sustainable future with the PROTECT30 initiative. This isn't just another dime-a-dozen CSR project—it’s a concerted effort aimed at conserving Sumatra's precious Bukit Tigapuluh landscape. These folks are playing the long...

Continue Reading
Nemazee Fellowship Advances Clemency and Justice Reform

Updated Category News Views 96

Nemazee Fellowship: A Catalyst for Change You're probably wondering what's really happening when a couple like Hassan and Nazie Nemazee put their name on a legal fellowship. Skipping the melodrama, it's all about making a dent in the criminal justice system. These two aren't just slapping their name on a plaque—they're throwing real support behind actions that matter....

Continue Reading
BlackLine's SAP Woes Spark Investor Scrutiny

Updated Category News Views 94

What Triggered This Investigation? Here we go again, folks. BlackLine's taking a hit, and it ain't pretty. They're reeling from a whopping 17.4% drop in their share price after cutting their fiscal 2026 outlook. You can bet the folks with stakes in BlackLine (NASDAQ:BL) are feeling the burn. This all comes down to a mess involving their SAP SolEx channel. Let's dive into...

Continue Reading

Top 5 Most Recently Viewed Articles

ImmunityBio Advances Towards EU Approval for Cancer Treatment

Updated Category News Views 95

ImmunityBio's Journey Towards EU Approval The European Medicines Agency (EMA) has made a significant recommendation toward approving ImmunityBio, Inc.’s Anktiva (nogapendekin alfa inbakicept), intended for use alongside Bacillus Calmette-Guérin (BCG) for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Clinical Trial Results and Findings This...

Continue Reading
Temperature Monitoring Systems Set to Reach $5.66 Billion by 2030

Updated Category News Views 139

Temperature Monitoring Systems Market Analysis and Growth Projections The temperature monitoring systems market, valued at USD 3.80 billion recently, is on a promising trajectory. It is expected to expand at a compound annual growth rate (CAGR) of 5.3%, reaching an impressive USD 5.66 billion by 2030. This growth can be attributed to several factors, including...

Continue Reading
Comparative Insights on Apple and Its Competitors' Performance

Updated Category News Views 336

Performance Insights into Apple and Industry Competitors In the ever-evolving realm of technology, understanding the dynamics of company performance is vital for investors and analysts. This analysis focuses on Apple Inc. (NASDAQ: AAPL) and its key competitors in the Technology Hardware, Storage & Peripherals sector. We'll delve into essential financial metrics, market...

Continue Reading
X Financial Achieves Impressive Growth in Recent Earnings

Updated Category News Views 108

X Financial Reveals Strong Q2 Performance X Financial (NYSE: XYF), a prominent player in the fintech industry, has reported robust financial results that highlight its significant growth and commitment to enhancing its service offering. The company recently disclosed its unaudited financial results for the second quarter, and the figures are quite remarkable. Q2 2025...

Continue Reading
Tyra Biosciences to Engage Investors at Major Conferences

Updated Category News Views 290

Tyra Biosciences to Engage Investors at Major Conferences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a pioneering biotechnology company dedicated to crafting next-generation precision medicines with a keen focus on Fibroblast Growth Factor Receptor (FGFR) biology. The company has great momentum as it takes strides in engaging with investors at a series of crucial investor...

Continue Reading